CN105566340A - White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof - Google Patents

White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof Download PDF

Info

Publication number
CN105566340A
CN105566340A CN201610035823.7A CN201610035823A CN105566340A CN 105566340 A CN105566340 A CN 105566340A CN 201610035823 A CN201610035823 A CN 201610035823A CN 105566340 A CN105566340 A CN 105566340A
Authority
CN
China
Prior art keywords
morusin
derivative
compound
ethyl acetate
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610035823.7A
Other languages
Chinese (zh)
Inventor
周英
黄俊飞
陆毅
刘雄利
周根
巩艺
林冰
俸婷婷
张敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201610035823.7A priority Critical patent/CN105566340A/en
Publication of CN105566340A publication Critical patent/CN105566340A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a Morusin derivative and a preparation method. A Morusin total-synthesis route is adopted to achieve a structure modification scheme, in the process of Morusin total synthesis, structure modification is carried out by replacing substituent groups of a reaction substrate, and a series of Morusin derivatives are synthesized. The Morusin total-synthesis route is an important anti-tumor activity lead compound, by means of synthesis of the derivatives, a compound source is provided for anti-tumor activity screening, and the derivative has great significance in finding a novel anti-tumor activity lead compound. The method is easy to operate and implement, the raw materials are low in synthesis cost and easy to obtain, synthesizing can be carried out in various kinds of organic solvent, and the derivative has good air stability, is wide in application range, and has good compatibility with various kinds of substituent groups. The derivatives have certain tumor cell growth inhibiting activity, and can be used as anti-tumor medicine or the anti-tumor medicine lead compound.

Description

A kind of White Mulberry Root-bark activeconstituents Morusin derivative and applications and preparation method thereof
Technical field
The present invention relates to field of pharmaceutical chemistry technology, especially a kind of White Mulberry Root-bark activeconstituents Morusin derivative and applications and preparation method thereof.
Background technology
White Mulberry Root-bark (MoriCortex) is the dry root skin of moraceae plants mulberry MorusalbaL., begin to be loaded in Shennong's Herbal, be classified as middle warp, history tree all records, the relieving cough and asthma Chinese medicine commonly used clinically, taste is sweet cold, and property is fallen, and master enters lung, with purging the lung of pathogenic fire heat, relieving asthma for speciality, energy inducing diuresis to remove edema, regulating fluid apssage, and can respectful lung qi fall.The chemical composition of White Mulberry Root-bark, based on Diels-Alder type adducts and flavonoid compound, also has terpene, coumarins, carbohydrate, sterols, volatile oil etc. in addition.Pharmacological research shows that White Mulberry Root-bark has multiple pharmacologically active, comprises antitumour activity.But detect through document and find not carry out more deep research to the anticancer active constituent of White Mulberry Root-bark.
Find through literature survey, Yean-JangLee seminar [Tetrahedron, 2010,66,1335-1340] reports Morusin and has stronger anti-tumor activity.Applicant team has no Morusin structure modified outcome bibliographical information through SciFinder retrieval.Therefore, structural modification is carried out to Cortex Mori (MoriCortex) activeconstituents Morusin, its structure activity relationship of further research and tumour mechanism thereof, by contributing to the determination of potential antineoplastic new target spot, have important researching value to the discovery of new type antineoplastic medicine.Further, synthesis Morusin derivative may produce series of new anti-tumor activity molecule, and their synthesis can provide compound source for antitumor activity screening, has great importance to the novel anti-tumor activity lead compound of searching.
Summary of the invention
The object of the invention is: a kind of White Mulberry Root-bark activeconstituents Morusin derivative and applications and preparation method thereof are provided, this compound and derivative thereof can as the important anti-tumor activity lead compounds of a class, to drug screening and pharmaceutical industry, there is important using value, and its synthetic method is very economical easy.
The present invention is achieved in that the application of a kind of White Mulberry Root-bark activeconstituents Morusin derivative at preparation control tumor disease medicine, and this compound has the structure as shown in logical formula I;
White Mulberry Root-bark activeconstituents Morusin derivative is in the application of preparation control tumor disease medicine
The preparation method of Morusin derivative, acidylate decarboxylic reaction is first there is with potassium ethyl malonate salt by the Benzoyl chloride 1 of corresponding replacement, generate intermediate 2, then there is Michael addition reaction with methylene acetone again in intermediate 2, obtain intermediate 3, then intermediate 3 and Phloroglucinol generation annulation, generate intermediate 4, intermediate 4 again with isoamyl olefine aldehydr generation annulation, generate Morusin derivative 5, Morusin derivative 5 and generate Morusin derivative 6 by there is Aldol addition reaction with the Grignard reagent of various replacement; Or Morusin derivative 5 obtains Morusin derivative 7 by sodium borohydride reduction carbonyl.
Morusin derivative synthetic route is as follows:
By adopting technique scheme, the present invention synthesizes Morusin derivative, it is the important anti-tumor activity lead compound of a class, and their synthesis can provide compound source for antitumor activity screening, has great importance to the novel anti-tumor activity lead compound of searching.Operation is simple in the present invention, and Material synthesis is cheaply easy to get, and can carry out, also have good air stability in various organic solvent, and suitability is wide, has good compatibility for various substituting group.
Accompanying drawing explanation
Accompanying drawing 1-4 is embodiments of the invention part Morusin derivative 1h-NMR spectrum and 13cNMR spectrogram.
Embodiment
The present embodiment is intended to set forth instead of limit the scope of the invention.Gained compound measures it with Inova400MHz NMR spectrometer with superconducting magnet (TMS is interior mark, Varian company of the U.S.) 1h-NMR spectrum and 13cNMR composes; With HRMS-ESI mass spectrograph (Micro tMq-TOF) its molecular weight is measured.Agents useful for same is analytical pure or chemical pure.
The Morusin derivative prepared by the present embodiment is in table 1, but it is emphasized that embodiment is intended to set forth instead of limit the scope of the invention.Morusin derivative of the present invention is not limited to the content represented by table 1.
(1), the synthesis of Morusin derivative 5a and the preparation of reaction intermediate thereof
Experimental implementation: get potassium ethyl malonate salt 1.00g(and be about 5.47mmol) and Magnesium Chloride Anhydrous 0.65g(be about 6.84mmol) in 25mL round-bottomed flask, add 6mL acetonitrile after instillation 0.55g triethylamine and dissolve, in stirred at ambient temperature 30min.The 0.48g(2.5mmol that instillation is subsequently dissolved with 2mL acetonitrile) 2,4-dimethoxy-benzoyl chlorides, then add triethylamine 0.06mL, stirred overnight at room temperature.Aftertreatment: first add 30mL water dilute reaction solution, then add 30 respectively, 20,20mL extraction into ethyl acetate, collect ethyl acetate layer.With 30mL saturated aqueous common salt cleaning ethyl acetate layer after anhydrous sodium sulfate drying, be spin-dried for, column chromatography (PE:EA=15:1) be separated obtain product 2a, productive rate 90%; HRMS (ESI-TOF) m/z:Calcd.forC 13h 16naO 5[M+Na] +: 275.0895; Found:275.0899.
Experimental implementation: get 0.452g(2mmol) 2a is in 25mL round-bottomed flask, use 10mL dissolve with ethanol after adding sodium ethylate 0.16g, stirring at room temperature 15 minutes, gets 0.162mL(2mmol subsequently) acrylketone in flask, stirring at room temperature 2h.Aftertreatment: add 5% hydrochloric acid reaction solution, then use 30 respectively, 20,20mL extraction into ethyl acetate aqueous phase, the oil reservoir that saturated common salt water washing has merged, is spin-dried for after anhydrous sodium sulfate drying, and column chromatography (PE:EA=10:1) is separated and obtains product 3a, productive rate 86%; HRMS (ESI-TOF) m/z:Calcd.forC 17h 22naO 6[M+Na] +: 345.1314; Found:345.1310.
Experimental implementation: get 0.38g(3mmol) 3a is in 25mL round-bottomed flask, add 0.126g (1mmol) Phloroglucinol again, with being placed in household microwave oven, under 640W, heating 8min, taking out subsequently and being down to room temperature, add acetic acid ethyl dissolution, cross leaching ethyl acetate layer, be spin-dried for, column chromatography (PE:EA=5:1) is separated and obtains product 4a, productive rate 45% 1h-NMR (CDCl 3, 100MHz) and δ: 2.09 (s, 3H), 2.21 (t, J=8.1Hz; 2H), 2.69 (t, J=6.0Hz, 2H); (3.67 s, 1H), 3.78 (s, 3H); (5.35 s, 1H), 6.43 (m, 2H); (7.26 d, J=4.2Hz, 2H), 7.885 (d; J=12.1Hz, 1H), 12.95 (s, 1H); 13cNMR (CDCl 3, 100MHz) and δ: 22.6,29.6,42.3,52.1,55.4,93.7,98.1,98.7,105.1,105.7,120.1,131.1,133.5,158.1,160.7,162.7,165.1,171.3,182.2,194.0,208.9; HRMS (ESI-TOF) m/z:Calcd.forC 21h 20naO 7[M+Na] +: 407.1106; Found:407.1108.
Experimental implementation: take 384mg (1mmol) 4a in 50mL round-bottomed flask, even instillation 85mg (1mmol) 3-methyl butene aldehyde, get anhydrous sodium carbonate system is covered, be placed in microwave oven, under 640W, heating is total to 20min at twice, acetic acid ethyl dissolution, and add water extraction, dry ethyl acetate layer, decompression is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 5a, productive rate 23%. 1HNMR(CDCl 3,400MHz)δ:1.45(s,6H),2.09(s,3H),2.57(t,J=7.2Hz,2H),2.69(m,2H),3.78(s,3H),3.87(s,3H),5.48(d,J=10.0Hz,1H),6.26(s,1H),6.55(d,J=2.6Hz,1H,),6.57(s,1H),6.61(d,J=2.4Hz,1H),7.26(s,1H),7.28(s,1H); 13CNMR(CDCl 3,100MHz)δ:20.3,28.2,29.3,29.7,41.9,55.5,55.6,76.8,77.6,98.8,99.7,100.9,104.9,114.4,115.0,120.3,126.7,131.2,152.4,158.2,159.2,160.4,161.7,162.7,182.4,208.3;HRMS(ESI-TOF)m/z:Calcd.forC 26H 26NaO 7[M+Na] +:473.1576;Found:473.1577.
(2), Morusin derivative 5c, the synthesis of 6c-1,6c-2 and 7c and the preparation of reaction intermediate 2c-4c thereof
Experimental implementation: get potassium ethyl malonate salt 1.00g(and be about 5.47mmol) and Magnesium Chloride Anhydrous 0.65g(be about 6.84mmol) in 25mL round-bottomed flask, add 6mL acetonitrile after instillation 0.55g triethylamine and dissolve, in stirred at ambient temperature 30min.The 0.48g(2.5mmol that instillation is subsequently dissolved with 2mL acetonitrile) o-chlorobenzoyl chloride 1c, then add triethylamine 0.06mL, stirred overnight at room temperature.Aftertreatment: first add 30mL water dilute reaction solution, then add 30 respectively, 20,20mL extraction into ethyl acetate, collect ethyl acetate layer.With 30mL saturated aqueous common salt cleaning ethyl acetate layer after anhydrous sodium sulfate drying, be spin-dried for, column chromatography (PE:EA=15:1) be separated obtain product 2c, productive rate 91%; 1h-NMR (CDCl 3, 400MHz) and δ: 1.24 (t, J=8.0Hz, 3H), 4.04 (s, 2H); 4.19 (m, J=4.2Hz, 2H), 7.31-7.37 (m, 1H); 7.43-7.44 (m, 2H), 7.61 (d, J=8.1Hz, 1H); 13c-NMR (CDCl 3, 100MHz) and δ: 14.0,49.1,61.4,130.0,130.6,130.1,130.7,131.0,132.6,166.9,194.70; HRMS (ESI-TOF) m/z:Calcd.forC 11h 11clNaO 3[M+Na] +: 249.0294; Found:249.0297.
Experimental implementation: get 0.452g(2mmol) 2c is in 25mL round-bottomed flask, use 10mL dissolve with ethanol after adding sodium ethylate 0.16g, stirring at room temperature 15 minutes, gets 0.162mL(2mmol subsequently) acrylketone in flask, stirring at room temperature 2h.Aftertreatment: add 5% hydrochloric acid reaction solution, use 30 more respectively, 20,20mL extraction into ethyl acetate aqueous phase, the oil reservoir that saturated common salt water washing has merged, be spin-dried for after anhydrous sodium sulfate drying, column chromatography (PE:EA=10:1) is separated and obtains product 3c, productive rate 87%, HRMS (ESI-TOF) m/z:Calcd.forC 15h 17clNaO 4[M+Na] +: 319.0713; Found:319.0713.
Experimental implementation: get 0.38g(3mmol) 3c is in 25mL round-bottomed flask; add 0.126g (1mmol) Phloroglucinol again; with being placed in household microwave oven; under 640W, heat 8min, take out subsequently and be down to room temperature, add acetic acid ethyl dissolution; cross leaching ethyl acetate layer; be spin-dried for, column chromatography (PE:EA=5:1) is separated and obtains product 4c, productive rate 66%; 1h-NMR (CDCl 3, 400MHz) and δ: 2.12 (s, 3H), 2.56 (s; 2H), 2.70 (s, 2H); 6.28 (d, J=4.0Hz, 2H); 7.26 (s, 1H), 740-7.49 (m; 3H), 7.53 (d, J=8.2Hz; 1H), 12.77 (s, 1H); 13c-NMR (CDCl 3, 100MHz) and δ: 19.9,29.7,41.7,93.9,99.3,105.1,120.1,127.1,130.1,130.6,131.5,131.7,133.3,157.9,160.3,162.3,162.5,182.1,208.7; HRMS (ESI-TOF) m/z:Calcd.forC 19h 15clNaO 5[M+Na] +: 381.0505; Found:381.0507.
Experimental implementation: get 0.358g(1mmol) 4c and 0.114mL3-Methylacrylaldehyde in 25mL round-bottomed flask, then adds 0.147g anhydrous sodium carbonate and is placed in household microwave oven, under 640W, heat 13min.Take out subsequently and be down to room temperature, add acetic acid ethyl dissolution, cross leaching ethyl acetate layer, be spin-dried for, column chromatography (PE:EA=9:1) is separated and obtains product 5c, weak yellow liquid, productive rate 19%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.81 (s, 1H), 7.56-7.53 (m; 1H), 7.51-7.46 (m, 1H), 7.45-7.40 (m; 2H), 6.59-6.52 (m, 1H), 6.29 (s; 1H), 5.51-5.46 (m, 1H), 2.75-2.65 (m; 2H), 2.62-2.50 (m, 2H), 2.08 (s; 3H), 1.45 (s, 6H); 13c-NMR (CDCl 3, 100MHz) and δ: 207.7,161.7,159.9,159.6,152.1,133.4,131.7,131.5,130.9; 130.7,130.2,128.8,127.1,120.3,114.7,105.0,101.0,100.1,78.1; 77.3,77.0,76.8,41.6,29.7,29.7,28.3,19.8,14.1,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 24h 21clNaO 5[M+Na] +: 447.0975; Found:447.0973.
Experimental implementation: take 424mg (1mmol) 5c in 25mLTHF, ice bath is down to sub-zero zero to system, adds excess methyl iodate magnesium (3.5eq), stir 2h under keeping ice bath, the cancellation that adds water is reacted, and adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 6c, productive rate 77%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.82 (s, 1H); (7.59-7.54 m, 1H), 7.51-7.46 (m; 1H), 7.44-7.42 (m, 1H); (7.26 s, 1H), 6.64-6.49 (m; 1H), 6.28 (s, 1H); (5.55-5.43 m, 1H), 2.51-2.27 (m; 2H), 1.79 (s, 1H); 1.72-1.68 (m; 2H), 1.45 (s, 6H); 1.12 (s, 6H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.3,161.8,159.7,159.6,152.2; 133.5,132.3,131.7,131.6,130.9,130.7; 130.2,128.8,127.0,126.9,122.0; 114.8,105.1,101.0,100.1,78.1; 77.3,77.0,76.8,70.5,42.1; 30.6,29.7,28.9,28.2,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 25h 25clNaO 5[M+Na] +: 463.1288; Found:463.1291.
Experimental implementation: take 424mg (1.0mmol) 5c in 25mLTHF, ice bath is down to sub-zero zero to system, it is excessive in fluorobenzenemagnesium bromide (3.5eq) to add, stir 3h under keeping ice bath, the cancellation that adds water is reacted, and adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 6c-2, productive rate 68%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.71 (s, 1H), 7.52-7.44 (m, 2H); (7.34-7.26 m, 3H), 6.94-6.82 (m, 2H); (6.58-6.49 m, 1H), 6.27 (s, 1H); (5.53-5.42 m, 1H), 4.13-4.11 (m, 1H); (2.04 s, 2H), 1.97 (s, 2H); (1.76 s, 1H), 1.44 (s, 9H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.3,161.6,159.7,152.2,143.0,142.9,131.6,131.4,130.6; 127.1,126.9,126.5,126.4,121.6,114.7,114.5,105.0,101.0,100.1; 78.1,77.3,77.0,76.8,73.9,42.2,29.7,28.3,14.2; HRMS (ESI-TOF) m/z:Calcd.forC 30h 26clFNaO 5[M+Na] +: 543.1350; Found:543.1352.
Experimental implementation: take 424mg (1.0mmol) 5c in 25mL methyl alcohol, ice bath adds excess sodium borohydrate (3.0eq) under stirring, stirring at room temperature 3h, with in rare HCl and superfluous sodium borohydride, adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:4) system in ethyl acetate, obtain pale yellow oily liquid body 7c, productive rate 88%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.93 (s, 1H); (7.56-7.52 m, 1H), 7.51-7.45 (m; 1H), 7.43-7.39 (m, 2H); (6.78-6.69 m, 1H), 6.28 (s; 1H), 5.65-5.58 (m, 1H); (3.70-3.60 m, 1H), 3.10 (s; 1H), 2.67-2.58 (m, 1H); 2.29-2.21 (m; 1H), 1.46 (s, 8H); 1.11-1.07 (m, 3H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.7,160.6,159.8,157.3,156.3,133.4,131.7,131.6,130.5; 130.2,128.8,128.1,127.0,121.2,115.4,105.5,104.9,94.8; 78.0,77.3,77.0,76.8,65.9,65.5,44.9,38.3,28.3; HRMS (ESI-TOF) m/z:Calcd.forC 24h 23clNaO 5[M+Na] +: 449.1131; Found:449.1133.
(3), Morusin derivative 5e, the synthesis of 6e-1,6e-2,6e-3 and 7e and the preparation of reaction intermediate 2e-4e thereof
Experimental implementation: get potassium ethyl malonate salt 1.00g(and be about 5.47mmol) and Magnesium Chloride Anhydrous 0.65g(be about 6.84mmol) in 25mL round-bottomed flask, add 6mL acetonitrile after instillation 0.55g triethylamine and dissolve, in stirred at ambient temperature 30min.The 0.48g(2.5mmol of instillation 2mL acetonitrile dissolving subsequently) adjacent bromo-benzoyl chloride 1e, then add triethylamine 0.06mL, stirred overnight at room temperature.Aftertreatment: first add 30mL water dilute reaction solution, then add 30 respectively, 20,20mL extraction into ethyl acetate, collect ethyl acetate layer.With 30mL saturated aqueous common salt cleaning ethyl acetate layer after anhydrous sodium sulfate drying, be spin-dried for, column chromatography (PE:EA=15:1) be separated obtain product 2e, productive rate 92%; 1h-NMR (CDCl 3, 400MHz) and δ: 1.26 (t, J=8.1Hz, 3H), 4.03 (s; 2H), 4.19 (m, J=12.0Hz, 2H), 7.32-7.42 (m; 2H), 7.49-7.54 (m, 1H), 7.63-7.65 (m, 1H); 13c-NMR (CDCl 3, 100MHz) and δ: 14.0,48.7,61.5,119.1,127.4,129.4,132.3,133.8,139.9,166.7,196.6; HRMS (ESI-TOF) m/z:Calcd.forC 11h 11brNaO 3[M+Na] +: 292.9789; Found:292.9786.
Experimental implementation: get 0.452g(2mmol) 2e in 25mL round-bottomed flask, use 10mL dissolve with ethanol after adding sodium ethylate 0.16g, stirring at room temperature 15 minutes, get 0.162mL (2mmol) acrylketone subsequently in flask, stirring at room temperature 2h.Aftertreatment: add 5% hydrochloric acid reaction solution, then use 30 respectively, 20,20mL extraction into ethyl acetate aqueous phase, the oil reservoir that saturated common salt water washing has merged, is spin-dried for after anhydrous sodium sulfate drying, and column chromatography (PE:EA=10:1) is separated and obtains product 3e, productive rate 85%; HRMS (ESI-TOF) m/z:Calcd.forC 15h 17brNaO 4[M+Na] +: 363.0207; Found:363.0204.
Experimental implementation: get 0.38g(3mmol) 3e is in 25mL round-bottomed flask; add 0.126g (1mmol) Phloroglucinol again; with being placed in household microwave oven; under 640W, heat 8min, take out subsequently and be down to room temperature, add acetic acid ethyl dissolution; cross leaching ethyl acetate layer; be spin-dried for, be separated through silicagel column column chromatography (PE:EA=5:1) and obtain product 4e, productive rate 57%; 1h-NMR (CDCl 3, 400MHz) and δ: 2.11 (s, 3H), 2.57 (d; J=8.1Hz, 2H), 2.70 (d; J=8.2Hz, 2H), 6.30 (s; 2H), 7.27 (s, 1H); 7.37-7.47 (m, 3H), 7.72 (m; 1H), 12.77 (s, 1H); 13c-NMR (CDCl 3, 100MHz) and δ: 19.8,29.6,41.7,93.9,99.3,105.1,119.8,122.6,127.6,130.64,131.8,133.2,133.5,157.9,161.4,162.2,162.5,182.1,208.2; HRMS (ESI-TOF) m/z:Calcd.forC 19h 15brNaO 5[M+Na] +: 425.0001; Found:425.0001.
Experimental implementation: get 0.358g(1mmol) 4e and 0.114mL3-Methylacrylaldehyde in 25mL round-bottomed flask, then adds 0.147g anhydrous sodium carbonate and is placed in microwave oven, under 640W, heat 13min.Take out subsequently and be down to room temperature, add acetic acid ethyl dissolution, cross leaching ethyl acetate layer, be spin-dried for, column chromatography (PE:EA=9:1) is separated and obtains product 5e, weak yellow liquid, productive rate 15%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.81 (s, 1H), 7.74-7.71 (m; 1H), 7.47-7.44 (m, 1H), 7.43-7.39 (m; 2H), 6.59-6.53 (m, 1H), 6.29 (s; 1H), 5.51-5.45 (m, 1H), 2.75-2.65 (m; 2H), 2.59-2.52 (m, 2H), 2.08 (s; 3H), 1.26 (s, 6H); 13c-NMR (CDCl 3, 100MHz) and δ: 207.7,182.3,161.7,161.1,159.6; 152.1,133.6,133.3,132.3,131.8,130.9; 130.8,128.8,127.6,127.1,122.7,120.0; 114.7,105.1,101.0,100.1,94.8,78.1; 77.3,77.0,76.8,41.6,30.6; 29.7,29.7,28.4,28.1,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 24h 21brNaO 5[M+Na] +: 491.0470; Found:491.0470.
Experimental implementation: take 468mg (1mmol) 5e in 25mLTHF, ice bath is down to sub-zero zero to system, adds excess methyl iodate magnesium (3.5eq), stir 2h under keeping ice bath, the cancellation that adds water is reacted, and adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 6e-1, productive rate 75%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.83 (s, 1H), 7.74 (d; J=8.2Hz, 1H), 7.50-7.45 (m, 1H); (7.44-7.40 m, 2H), 6.58 (d, J=10.0Hz; 1H), 6.29 (s, 1H), 5.49 (d; J=10.0Hz, 1H), 2.52-2.42 (m; 1H), 2.34-2.25 (m, 1H); (1.74-1.63 m, 2H), 1.58 (dd; J=11.2,5.3Hz, 1H); (1.45 d, J=13.7Hz, 6H); (1.12 d, J=4.9Hz, 6H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.3,161.7,160.8,159.6,133.7; 133.3,131.7,130.9,130.7,128.8; 127.5,127.0,122.7,121.6,114.7; 105.1,101.0,100.0,78.1,77.3; 77.0,76.7,70.4,42.1,30.5; 28.9,28.8,28.4,28.1,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 25h 25brNaO 5[M+Na] +: 507.0783; Found:507.0785.
Experimental implementation: take 468mg (1.0mmol) 5e in 25mLTHF, ice bath is down to sub-zero zero to system, it is excessive in fluorobenzenemagnesium bromide (3.5eq) to add, stir 3h under keeping ice bath, the cancellation that adds water is reacted, and adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 6e-2, productive rate 71%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.88-12.56 (m, 1H); (7.72-7.66 m, 1H), 7.44-7.36 (m; 2H), 7.33-7.28 (m, 1H); (7.27-7.22 m, 2H), 6.94-6.81 (m; 2H), 6.60-6.52 (m, 1H); (6.28 s, 1H), 5.54-5.44 (m; 1H), 2.05 (s, 2H); 2.01-1.93 (m; 2H), 1.78 (s, 1H); 1.49-1.41 (m, 9H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.4,162.4,162.3,161.6,160.9; 160.8,160.4,160.3,159.7,152.1; 142.9,133.5,133.4,133.3,131.6; 130.6,127.5,127.4,127.1,126.5; 126.5,126.4,126.3,122.7,122.6; 121.4,121.3,114.7,114.7,114.7; 114.6,114.5,105.0,101.0,100.1; 78.1,77.3,77.0,76.8,73.9; 73.8,42.4,42.1,31.1,30.7; 29.7,28.3,28.1,28.0,14.2; HRMS (ESI-TOF) m/z:Calcd.forC 30h 26brFNaO 5[M+Na] +: 587.0845; Found:587.0845.
Experimental implementation: take 468mg (1.0mmol) 5e in 25mLTHF, ice bath is down to sub-zero zero to system, it is excessive in fluorobenzenemagnesium bromide (3.5eq) to add, stir 3h under keeping ice bath, the cancellation that adds water is reacted, and adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:5) system in ethyl acetate, obtain pale yellow oily liquid body 6e-3, productive rate 67%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.86-12.53 (m, 1H), 7.72-7.65 (m; 1H), 7.42-7.17 (m, 7H), 7.16-7.09 (m; 1H), 6.60-6.52 (m, 1H), 6.27 (s; 1H), 5.51-5.45 (m, 1H), 2.99 (s; 1H), 2.42-2.13 (m, 2H), 2.08-1.98 (m; 2H), 1.47-1.42 (m, 9H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.4,161.6,160.8,159.6,152.1,147.3,133.5; 133.4,133.3,132.3,131.6,130.9,130.6,128.8,128.0; 127.9,127.5,127.4,127.0,126.3,126.2,124.7,124.6; 122.6,121.5,121.4,114.7,105.0,101.0,100.0; 78.1,77.3,77.0,76.8,74.1,42.2,41.9; 30.9,30.7,30.5,29.7,28.3,28.1,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 30h 27brNaO 5[M+Na] +: 569.0939; Found:569.0941.
Experimental implementation: take 468mg (1.0mmol) 5e in 25mL methyl alcohol, ice bath adds excess sodium borohydrate (3.0eq) under stirring, stirring at room temperature 3h, with in rare HCl and superfluous sodium borohydride, adds extraction into ethyl acetate, dry ethyl acetate layer, is spin-dried for.Be separated with silica gel column chromatography under sherwood oil (1:4) system in ethyl acetate, obtain pale yellow oily liquid body 7e, productive rate 83%; 1h-NMR (CDCl 3, 400MHz) and δ: 12.78-12.60 (m, 1H), 7.78-7.68 (m; 1H), 7.50-7.45 (m, 1H); (7.44-7.38 m, 2H), 6.64-6.52 (m; 1H), 6.30 (s, 1H); (5.53-5.46 m, 1H), 3.70-3.59 (m; 1H), 3.11-2.98 (m, 1H); (2.71-2.58 m, 1H), 2.40-2.29 (m; 1H), 2.26-2.13 (m, 1H); (1.75-1.66 m, 1H), 1.48-1.44 (m; 6H), 1.14-1.07 (m, 3H); 13c-NMR (CDCl 3, 100MHz) and δ: 182.9,161.7,161.6,159.9,152.2; 133.7,133.4,133.4,131.8,130.9,130.7; 130.6,128.8,127.6,127.5,127.1,122.9; 122.6,121.2,120.9,114.7,104.9,101.0; 100.2,78.2,77.3,77.0,76.8,38.6; 37.9,30.6,29.7,28.4,28.2,13.7; HRMS (ESI-TOF) m/z:Calcd.forC 24h 23brNaO 5[M+Na] +: 493.0626; Found:493.0628.
Formula of the present invention (1) Morusin derivative has important anti-tumor activity, external to human lung carcinoma cell (A549), human leukemia cell (K562), the cell toxicity test of human prostate (PC-3) totally three strain tumour cells shows: the Morusin derivative of the structure shown in this type of formula (1) is inhibited to growth of tumour cell, likely develops into new control tumour medicine or control tumour medicine lead compound.Mandatory declaration, Pharmacological Examples of the present invention is for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to application claims protection to the simple modifications that the present invention carries out and denies scope.
Pharmacological Examples 1:Morusin derivative 5a, 5c, 5e, 6c-1,6c-2,6e-1,6e-2,6e-3,7c or 7e are to the cytotoxicity of A549 cell
A549(Non-small cell lung carcinoma lung cancer) use DMEM culture medium culturing, containing the foetal calf serum of 10% in substratum, the penicillin of 100U/mL and 100U/mL Streptomycin sulphate.Cell joins in 96 holes with the concentration of 4000 cells in every hole, at 37 DEG C containing 5%CO 2cultivate 24 hours in the incubator of damp atmosphere.
The mensuration improvement mtt assay of cell survival rate.Cell after 24 hours hatch, the compound Morusin derivative 5a will newly joined respectively, 5c, 5e, 6c-1,6c-2,6e-1, the dimethyl sulphoxide solution of 6e-2,6e-3,7c or 7e joins in each hole with concentration gradient, compound ultimate density in hole is made to be respectively 5 μm of ol/L, 10 μm of ol/L, 20 μm of ol/L, 40 μm of ol/L and 80 μm ol/L.After 48 hours, every hole adds 10 μ LMTT(5mg/mL) phosphate buffered saline buffer, then to continue 37 oafter C cultivates 4 hours, within centrifugal 5 minutes, remove unconverted MTT, in every hole, add 150 μ L dimethyl sulfoxide (DMSO).With the MTT crystal formazan (formazan) of dissolving and reducing, measure OD value by microplate reader at 490nm wavelength.Wherein Morusin derivative 5a, 5c, 5e, 6c-1,6c-2,6e-1,6e-2,6e-3,7c or 7e are to A549 cell 503nhibiting concentration IC 50obtained by spss software (19 version) analysis.Compound 5a is to the IC of A549 tumour cell 50be 28.3 μm of ol/L; Compound 5c is to the IC of A549 tumour cell 50be 19.4 μm of ol/L; Compound 5e is to the IC of A549 tumour cell 50be 28.7 μm of ol/L; Compound 6c-1 is to the IC of A549 tumour cell 50be 8.9 μm of ol/L; Compound 6c-2 is to the IC of A549 tumour cell 50be 3.5 μm of ol/L; Compound 6e-1 is to the IC of A549 tumour cell 50be 7.8 μm of ol/L; Compound 6e-2 is to the IC of A549 tumour cell 50be 8.7 μm of ol/L; Compound 6e-3 is to the IC of A549 tumour cell 50be 2.7 μm of ol/L; Compound 7c is to the IC of A549 tumour cell 50be 12.3 μm of ol/L; Compound 7e is to the IC of A549 tumour cell 50be 15.6 μm of ol/L; And positive control cis-platinum is to the IC of A549 tumour cell 50be 25.7 μm of ol/L.
Experiment conclusion: A549 cell is that test compounds is to the Cytotoxic effective tool of tumour cell and evaluation index.This experiment shows that the Morusin derivative shown in this type of formula (1) has stronger cytotoxicity to A549 cell, better with the oncotherapy one line same order of magnitude of medication cis-platinum or specific activity cis-platinum, likely develop into the new medicine with antitumor action or lead compound.
Pharmacological Examples 2:Morusin derivative 5a, 5c, 5e, 6c-1,6c-2,6e-1,6e-2,6e-3,7c or 7e are to the cytotoxicity of K562 cell
K562(people's chronic myelogenous leukemia cell) use RPMI-1640 culture medium culturing, containing the foetal calf serum of 10% in substratum, the penicillin of 100U/mL and 100U/mL Streptomycin sulphate.Cell joins in 96 holes with the concentration of 5000 cells in every hole, at 37 DEG C containing 5%CO 2cultivate 24 hours in the incubator of damp atmosphere.
The mensuration improvement mtt assay of cell survival rate.Concrete grammar is as Pharmacological Examples 1.Compound 5a is to the IC of K562 tumour cell 50be 26.8 μm of ol/L; Compound 5c is to the IC of K562 tumour cell 50be 13.4 μm of ol/L; Compound 5e is to the IC of K562 tumour cell 50be 23.1 μm of ol/L; Compound 6c-1 is to the IC of K562 tumour cell 50be 5.8 μm of ol/L; Compound 6c-2 is to the IC of K562 tumour cell 50be 9.1 μm of ol/L; Compound 6e-1 is to the IC of K562 tumour cell 50be 8.5 μm of ol/L; Compound 6e-2 is to the IC of K562 tumour cell 50be 7.2 μm of ol/L; Compound 6e-3 is to the IC of K562 tumour cell 50be 2.3 μm of ol/L; Compound 7c is to the IC of K562 tumour cell 50be 42.3 μm of ol/L; Compound 7e is to the IC of K562 tumour cell 50be 32.5 μm of ol/L; And positive control cis-platinum is to the IC of K562 tumour cell 50be 24.6 μm of ol/L.
Experiment conclusion: K562 cell is that test compounds is to the Cytotoxic effective tool of tumour cell and evaluation index.This experiment shows that the Morusin derivative shown in this type of formula (1) has stronger cytotoxicity to K562 cell, better with the oncotherapy one line same order of magnitude of medication cis-platinum or specific activity cis-platinum, likely develop into the new medicine with antitumor action or lead compound.
Pharmacological Examples 3:Morusin derivative 5a, 5c, 5e, 6c-1,6c-2,6e-1,6e-2,6e-3,7c or 7e are to the cytotoxicity of PC-3 cell
PC-3(human prostata cancer) cell RPMI-1640 culture medium culturing, containing the foetal calf serum of 10% in substratum, the Streptomycin sulphate of 100U/mL penicillin and 100U/mL.Cell joins in 96 holes, 37 with the concentration of 5000 cells in every hole oc is containing 5%CO 2cultivate 24 hours in the incubator of damp atmosphere.
The mensuration improvement mtt assay of cell survival rate.Concrete grammar is as Pharmacological Examples 1.Compound 5a is to the IC of PC-3 tumour cell 50be 47.54 μm of ol/L; Compound 5c is to the IC of PC-3 tumour cell 50be 25.32 μm of ol/L; Compound 5e is to the IC of PC-3 tumour cell 50be 28.19 μm of ol/L; Compound 6c-1 is to the IC of PC-3 tumour cell 50be 10.64 μm of ol/L; Compound 6c-2 is to the IC of PC-3 tumour cell 50be 11.80 μm of ol/L; Compound 6e-1 is to the IC of PC-3 tumour cell 50be 19.54 μm of ol/L; Compound 6e-2 is to the IC of PC-3 tumour cell 50be 8.97 μm of ol/L; Compound 6e-3 is to the IC of PC-3 tumour cell 50be 9.05 μm of ol/L; Compound 7c is to the IC of PC-3 tumour cell 50be 32.61 μm of ol/L; Compound 7e is to the IC of PC-3 tumour cell 50be 34.67 μm of ol/L; And positive control cis-platinum is to the IC of PC-3 tumour cell 50be 26.2 μm of ol/L.
Experiment conclusion: PC-3 cell is that test compounds is to the Cytotoxic effective tool of tumour cell and evaluation index.This experiment shows that the Morusin derivative shown in this type of formula (1) has stronger cytotoxicity to PC-3 cell, better with the oncotherapy one line same order of magnitude of medication cis-platinum or specific activity cis-platinum, likely develop into the new medicine with antitumor action or lead compound.
From above Pharmacological Examples, we can find out that these Morusin derivatives all show certain cytotoxicity to this three strains tumour cell.These compounds visible have the potentiality that exploitation becomes antitumor drug or lead compound, are worth continuing further investigation and go down.

Claims (3)

1. a White Mulberry Root-bark activeconstituents Morusin derivative, is characterized in that: this compound has the structure as shown in logical formula I:
。
2. a White Mulberry Root-bark activeconstituents Morusin derivative according to claim 1 is in the application preparing control tumor disease medicine.
3. the preparation method of a Morusin derivative as claimed in claim 1, it is characterized in that: by Benzoyl chloride 1 and the potassium ethyl malonate salt of corresponding replacement, acidylate decarboxylic reaction first occurs, generate intermediate 2, then there is Michael addition reaction with methylene acetone again in intermediate 2, obtain intermediate 3, then intermediate 3 and Phloroglucinol generation annulation, generate intermediate 4, intermediate 4 again with isoamyl olefine aldehydr generation annulation, generate Morusin derivative 5, Morusin derivative 5 generates Morusin derivative 6 by there is Aldol addition reaction with the Grignard reagent of various replacement, or Morusin derivative 5 obtains Morusin derivative 7 by sodium borohydride reduction carbonyl,
Morusin derivative synthetic route is as follows:
。
CN201610035823.7A 2016-01-20 2016-01-20 White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof Pending CN105566340A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610035823.7A CN105566340A (en) 2016-01-20 2016-01-20 White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610035823.7A CN105566340A (en) 2016-01-20 2016-01-20 White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105566340A true CN105566340A (en) 2016-05-11

Family

ID=55877029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610035823.7A Pending CN105566340A (en) 2016-01-20 2016-01-20 White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105566340A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117234A (en) * 2016-06-28 2016-11-16 贵州大学 Morusin skeleton splicing convolutamydine A skeleton compounds and preparation method and application
CN110483543A (en) * 2019-09-17 2019-11-22 西北大学 One breeder mulberry root extract, extraction separation method and its application
CN115212199A (en) * 2022-05-24 2022-10-21 核工业总医院 Application of small molecular compound in preparation of medicine for treating diffuse large B cell lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107152A (en) * 1994-02-15 1995-08-23 罗士德 Compound for inhibition of virus HIV of AIDS
US5859050A (en) * 1994-08-03 1999-01-12 Sarawak Medichem Pharmaceuticals, Inc. Method for the preparation of (+)-calanolide A and analogues thereof
CN101265250A (en) * 2007-03-16 2008-09-17 中国科学院上海药物研究所 Substituted flavonoids and preparation method, application and pharmaceutical composition thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107152A (en) * 1994-02-15 1995-08-23 罗士德 Compound for inhibition of virus HIV of AIDS
US5859050A (en) * 1994-08-03 1999-01-12 Sarawak Medichem Pharmaceuticals, Inc. Method for the preparation of (+)-calanolide A and analogues thereof
CN101265250A (en) * 2007-03-16 2008-09-17 中国科学院上海药物研究所 Substituted flavonoids and preparation method, application and pharmaceutical composition thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANA ZELOVÁ等，: ""Evaluation of Anti-Inflammatory Activity of Prenylated Substances Isolated from Morus alba and Morus nigra"", 《J. NAT. PROD.》 *
刑其毅等编，: "《基础有机化学.上册》", 30 June 2005 *
安永斌等，: ""格氏反应合成新方法在环丙沙星合成中的应用"", 《中国抗生素杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117234A (en) * 2016-06-28 2016-11-16 贵州大学 Morusin skeleton splicing convolutamydine A skeleton compounds and preparation method and application
CN106117234B (en) * 2016-06-28 2019-05-10 贵州大学 Morusin skeleton splices convolutamydine A skeleton class compound and preparation method and application
CN110483543A (en) * 2019-09-17 2019-11-22 西北大学 One breeder mulberry root extract, extraction separation method and its application
CN115212199A (en) * 2022-05-24 2022-10-21 核工业总医院 Application of small molecular compound in preparation of medicine for treating diffuse large B cell lymphoma

Similar Documents

Publication Publication Date Title
Majeed et al. Bakuchiol derivatives as novel and potent cytotoxic agents: A report
CN105566340A (en) White mulberry root-bark active ingredient Morusin derivative and application and preparation method thereof
CN108864024A (en) A kind of Scutellarein mustargen analog derivative and its preparation method and application
Zhang et al. Cytotoxicity of synthesized 1, 4-naphthoquinone oxime derivatives on selected human cancer cell lines
Suryawanshi et al. The isochroman-and 1, 3-dihydroisobenzofuran-annulation on carbohydrate templates via [2+ 2+ 2]-cyclotrimerization and synthesis of some tricyclic nucleosides
CN105663112A (en) Application and preparation method of Morusignin L and derivatives thereof
CN110003231A (en) 1,1- spiral shell norbornane-pyrans simultaneously [4,3-b] chromone compounds and its preparation method and application
Guan et al. Approaches to unsaturated analogues of nucleosides comprising four-and six-membered rings
CN107056680A (en) Spiral shell [indoline of cyclopropane 1,3 '] 2 ' ketone compounds and medicinal usage containing difluoromethyl
Jin et al. Gold (I)-Initiated Cycloisomerization/Diels–Alder/Retro-Diels–Alder Cascade Strategy to Biaryls
Bringmann et al. QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids
Zhou et al. Carbocyclic 4′-epi-formycin
Lin et al. Structure–activity relationship study of growth inhibitory 2-styrylchromones against carcinoma cells
Zhao et al. Synthesis of rupestonic acid derivatives with antiviral activity
Che et al. Combinatorial synthesis of a series of paeonol-based phenylsulfonyl hydrazone derivatives as insecticidal agents
Kitayama et al. Remarkable synthesis and structure of allene type zerumbone
Yang et al. Synthesis of novel spin-labeled podophyllotoxin derivatives as potential antineoplastic agents: Part XXV
CN107641109B (en) A kind of flavonoids and its preparation method and application
CN103524556B (en) SF-277 aminophosphonate ester derivatives and synthetic method thereof and application
CN101407522A (en) Preparation of amyrolin and derivatives thereof
CN104693194A (en) 3-(2-acrylate)-3'-nitroisoxazole oxoindole compound as well as preparation method and application thereof
Esho et al. NMR conformational analysis of p-tolyl furanopyrimidine 2′-deoxyribonucleoside and crystal structure of its 3′, 5′-di-O-acetyl derivative
Mudiganti et al. Efficient synthesis of cis-and trans-3, 4-dihydroxy-3, 4-dihydromollugin
CN103864881B (en) Oleanolic Acid-uridine conjugate and its preparation method and application
Chen et al. Efficient capture of difluorocarbene by pyridinium 1, 4-zwitterionic thiolates: A concise synthesis of difluoromethylene-containing 1, 4-thiazine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160511

RJ01 Rejection of invention patent application after publication